| pubmed-article:20558056 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0205208 | lld:lifeskim |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20558056 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:20558056 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:20558056 | pubmed:dateCreated | 2010-9-27 | lld:pubmed |
| pubmed-article:20558056 | pubmed:abstractText | To evaluate maximum tolerated dose and recommended dose (RD) for phase II studies of topotecan (TPT) combined with temozolomide (TMZ) (TOTEM) in children and adolescents with relapsed or refractory solid malignancies. | lld:pubmed |
| pubmed-article:20558056 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20558056 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20558056 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20558056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20558056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20558056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20558056 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20558056 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:20558056 | pubmed:issn | 1879-0852 | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:GeoergerBirgi... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:VassalGillesG | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:ChatelutEtien... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:LeblondPierre... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:CorradiniNadè... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:Landman-Parke... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:DiasNathalieN | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:RubieHervéH | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:Le... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:ChastagnerPas... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:FrappazDidier... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:PaciAngeloA | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:AertsIsabelle... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:DjafariLatifa... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:GentetJean-Cl... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:PasquetMarlèn... | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:NdiayeAnnaA | lld:pubmed |
| pubmed-article:20558056 | pubmed:author | pubmed-author:SchmittAntoni... | lld:pubmed |
| pubmed-article:20558056 | pubmed:copyrightInfo | Copyright © 2010. Published by Elsevier Ltd. | lld:pubmed |
| pubmed-article:20558056 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20558056 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:20558056 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20558056 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20558056 | pubmed:pagination | 2763-70 | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:meshHeading | pubmed-meshheading:20558056... | lld:pubmed |
| pubmed-article:20558056 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20558056 | pubmed:articleTitle | Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. | lld:pubmed |
| pubmed-article:20558056 | pubmed:affiliation | Hôpital des Enfants, Toulouse, France. rubie.h@chu-toulouse.fr | lld:pubmed |
| pubmed-article:20558056 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20558056 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20558056 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:20558056 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
